Grifols Pharmaceutical Technology (Shanghai) Co. Ltd

Grifols China representative office was established in 2010 and obtained the trading license as Grifols Pharmaceutical Technology (Shanghai) Co. Ltd in 2016. Based in Shanghai, with a branch office in Beijing, we cover mainland China market.

We offer a comprehensive portfolio of products and services from the Bioscience and Diagnostics divisions, including Human Albumin, Immunohematology and NAT testing products. Safety and quality are our top priorities as we deliver on our mission: improving the health and well-being of people around the world.

Unit 901-903, Tower 2, No. 1539, West Nanjing Rd., 
Jing'an District, Shanghai 200040
PEOPLES REPUBLIC OF CHINA

Contact information
Tel. +8621 6020 1510
Mail: info.china@grifols.com

Contact Us

Thank you for contacting us. We will reply as soon as possible.

ACCEPT

Thank you for your interest in learning more about our company. We care about your questions and concerns and we will reply you as soon as possible. Please complete all required fields as this will enable us to process your request more efficiently. The company identified in this section is the data controller and will process your personal data based on your consent as expressed in this form. You can exercise your rights of access, rectification, erasure and other data protection rights and obtain additional information on how your personal data is processed in the Privacy Policy

Text to Identify
DATA PROTECTION INFORMATION
Data controller The Grifols' group company to which you have submitted the request
Purpose To attend your requests of information and/or suggestions
Legal basis Consent
Recipients Grifols' group companies
Rights To access, rectify or erase, as well as any other rights as specified in the additional information layer
Additional information You may access the additional and detailed information on data protection here.

Quality policy

The company's mission and commitment to quality and stakeholder involvement are outlined in its quality policy statement.